Share This Page
Drugs in ATC Class S01F
✉ Email this page to a colleague
Subclasses in ATC: S01F - MYDRIATICS AND CYCLOPLEGICS
S01F Market Analysis and Financial Projection
The ATC Class S01F (Mydriatics and Cycloplegics) encompasses critical ophthalmic agents used for diagnostic and therapeutic purposes. This analysis explores the market dynamics, key therapeutic agents, and evolving patent landscape shaping this sector.
Market Dynamics of S01F Agents
Growth Drivers and Sales Trends
- Belgium-Luxembourg Market: In 2019, ophthalmologicals (S01) ranked among the top 5 fastest-growing ATC classes, with unit growth of 160,610 and value growth of €9.5M+ in July alone[2][7]. Mydriatics like tropicamide and cyclopentolate contribute significantly to this demand due to routine eye exams and surgical procedures.
- Global Mydriasis Market: Projected to grow at a 6.1% CAGR (2025–2035), reaching $1.23 billion[16]. Key drivers include rising diabetic retinopathy cases and advancements in drug formulations (e.g., combination drops).
Key Therapeutic Agents
| Drug Class | Examples | Mechanism | Clinical Use |
|---|---|---|---|
| Anticholinergics | Atropine, Tropicamide | Block muscarinic receptors | Cycloplegia, pupil dilation |
| Sympathomimetics | Phenylephrine, Ephedrine | Activate α-adrenergic receptors | Pupil dilation (without cycloplegia) |
Combination Therapies: A tropicamide 0.8% + phenylephrine 5% formulation outperforms tropicamide 1% alone, achieving faster and more sustained mydriasis[12]. This underscores a shift toward enhanced efficacy through drug synergies.
Patent Landscape and Innovation Trends
Current IP Activity
- Low Novelty in Core Agents: Established drugs like atropine and scopolamine have 0 active US patents[5][13], reflecting generics dominance. However, 6,436 patent applications for atropine sulfate indicate ongoing formulation improvements[5].
- Emerging Innovations:
- Drug Delivery Systems: Patent applications focus on iontophoretic delivery and sustained-release formulations to reduce dosing frequency[4].
- Combination Products: Fixed-dose combinations (e.g., phenylephrine + ketorolac) are protected under subclass S01FB51[1][10].
Patent Challenges
- Examination Hurdles: 74–78% of ophthalmic patents include experimental data, yet 80–90% face initial rejections during examination[4]. Common objections relate to non-obviousness and prior art.
- USPTO Backlogs: With a 26.2-month average pendency for patents in 2025, delays may slow commercialization of new S01F formulations[17].
Strategic Insights for Stakeholders
Opportunities
- Combo-Product Development: Leverage synergies between anticholinergics and sympathomimetics to improve efficacy[12].
- Targeted Delivery: Invest in nanoparticle or gel-based systems to prolong mydriatic effects[4][16].
- Emerging Markets: Expand in regions with growing diabetic populations (e.g., Asia-Pacific), where mydriasis demand is rising[16].
Risks
- Generic Competition: Off-patent status of key drugs pressures pricing.
- Regulatory Scrutiny: Safety concerns (e.g., systemic absorption in infants[6]) may complicate approvals for new formulations.
The S01F market remains robust due to irreplaceable diagnostic applications, while innovation focuses on delivery optimization and combination therapies. Stakeholders must navigate a complex IP environment marked by formulation patents and regulatory challenges to capitalize on growth opportunities.
References
- https://en.wikipedia.org/wiki/ATC_code_S01
- https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2019/belgian-reg-med-best-performers-for-july-2019.pdf?la=en&hash=EC30C5B2F4035D704D9E4BCA873B4E04
- https://www.knowmade.com/patent-analytics-services/patent-report/semiconductor-patent-landscape/semiconductor-advanced-packaging-patent-landscape/hybrid-bonding-patent-landscape-analysis-2024/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2709006/
- https://www.drugpatentwatch.com/p/generic-api/ATROPINE+SULFATE
- https://www.medicines.org.uk/emc/product/1610/smpc
- https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2019/belgian-reg-med-best-peformers-for-june-2019.pdf?la=en&hash=53ED99C879C5141F1E4DC3ECC69CFEE4
- https://www.knowmade.com/patent-analytics-services/patent-report/gan-electronics-patent-landscape-analysis-2023/
- https://blog.tbrc.info/2025/01/air-traffic-control-industry/
- https://www.wikidoc.org/index.php/ATC_code_S01
- https://ip.com/blog/2025-patent-trends-challenges-and-innovations-shaping-the-future-of-technology/
- https://aimdrjournal.com/wp-content/uploads/2021/08/OT2_OA_Thesis-1-part-1-eDI.pdf
- https://go.drugbank.com/drugs/DB00747
- https://www.taiwannews.com.tw/en/news/6062309
- https://go.drugbank.com/drugs/DB00979
- https://www.imarcgroup.com/mydriasis-market
- https://www.morganlewis.com/pubs/2025/03/uspto-in-2025-leadership-operational-legislative-and-policy-changes-to-watch
- https://atcddd.fhi.no/filearchive/publications/2025_guidelines__final_web.pdf
More… ↓
